ARTICLE | Company News
Phase-1, Boehringer Ingeheim diagnostic deal
February 7, 2001 8:00 AM UTC
Phase-1 (Santa Fe, N.M.), a developer of molecular toxicology technologies, and Boehringer Ingelheim Pharmaceuticals (Ridgefield, Conn.) will develop diagnostics to identify patients that will suffer ...